Becton, Dickinson and Company (BDX) Expected to Post Earnings on Thursday

Becton, Dickinson and Company (NYSE:BDX) is anticipated to issue its Q3 2026 results before the market opens on Thursday, August 6th. Analysts expect Becton, Dickinson and Company to announce earnings of $3.14 per share and revenue of $4.8871 billion for the quarter. Becton, Dickinson and Company has set its FY 2026 guidance at 12.520-12.720 EPS. Parties can find conference call details on the company’s upcoming Q3 2026 earning summary page for the latest details on the call scheduled for Thursday, August 6, 2026 at 8:00 AM ET.

Becton, Dickinson and Company (NYSE:BDX) last issued its earnings results on Thursday, May 7th. The medical instruments supplier reported $2.90 EPS for the quarter, beating analysts’ consensus estimates of $2.77 by $0.13. Becton, Dickinson and Company had a return on equity of 15.37% and a net margin of 5.33%.The firm had revenue of $4.71 billion for the quarter, compared to analyst estimates of $4.67 billion. During the same quarter in the prior year, the firm earned $3.35 earnings per share. Becton, Dickinson and Company’s revenue for the quarter was up 5.2% on a year-over-year basis. On average, analysts expect Becton, Dickinson and Company to post $13 EPS for the current fiscal year and $13 EPS for the next fiscal year.

Becton, Dickinson and Company Stock Performance

BDX opened at $169.86 on Tuesday. The company has a current ratio of 0.94, a quick ratio of 0.55 and a debt-to-equity ratio of 0.62. Becton, Dickinson and Company has a 12-month low of $127.59 and a 12-month high of $187.35. The firm has a 50 day moving average of $152.29 and a two-hundred day moving average of $163.15. The firm has a market capitalization of $46.80 billion, a PE ratio of 43.00, a P/E/G ratio of 11.80 and a beta of 0.21.

Becton, Dickinson and Company Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, September 30th. Stockholders of record on Wednesday, September 9th will be paid a $1.05 dividend. The ex-dividend date is Wednesday, September 9th. This represents a $4.20 dividend on an annualized basis and a dividend yield of 2.5%. Becton, Dickinson and Company’s dividend payout ratio is presently 106.33%.

Insider Buying and Selling at Becton, Dickinson and Company

In other Becton, Dickinson and Company news, CEO Thomas E. Polen, Jr. sold 2,764 shares of the company’s stock in a transaction on Monday, June 1st. The shares were sold at an average price of $146.35, for a total transaction of $404,511.40. Following the completion of the transaction, the chief executive officer directly owned 110,163 shares in the company, valued at approximately $16,122,355.05. This represents a 2.45% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Michael David Garrison sold 1,100 shares of the firm’s stock in a transaction dated Wednesday, June 24th. The shares were sold at an average price of $145.66, for a total transaction of $160,226.00. Following the completion of the transaction, the executive vice president directly owned 13,172 shares in the company, valued at $1,918,633.52. This represents a 7.71% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders sold 5,189 shares of company stock valued at $765,661. 0.40% of the stock is owned by insiders.

Institutional Trading of Becton, Dickinson and Company

Several large investors have recently bought and sold shares of BDX. Brighton Jones LLC increased its stake in Becton, Dickinson and Company by 98.2% during the fourth quarter. Brighton Jones LLC now owns 1,770 shares of the medical instruments supplier’s stock worth $401,000 after purchasing an additional 877 shares during the period. Caden Capital Partners LP purchased a new stake in Becton, Dickinson and Company during the 4th quarter worth approximately $101,000. Acumen Wealth Advisors LLC acquired a new stake in Becton, Dickinson and Company during the 4th quarter worth approximately $120,000. Bank of Jackson Hole Trust lifted its holdings in Becton, Dickinson and Company by 28.8% during the 4th quarter. Bank of Jackson Hole Trust now owns 649 shares of the medical instruments supplier’s stock worth $126,000 after buying an additional 145 shares in the last quarter. Finally, Zions Bancorporation National Association UT boosted its position in Becton, Dickinson and Company by 18.3% in the 4th quarter. Zions Bancorporation National Association UT now owns 962 shares of the medical instruments supplier’s stock valued at $187,000 after buying an additional 149 shares during the period. Hedge funds and other institutional investors own 86.97% of the company’s stock.

Wall Street Analysts Forecast Growth

BDX has been the subject of a number of research reports. Stifel Nicolaus decreased their target price on shares of Becton, Dickinson and Company from $215.00 to $175.00 in a research report on Thursday, May 7th. TD Cowen reduced their price objective on Becton, Dickinson and Company from $189.00 to $163.00 and set a “hold” rating for the company in a research note on Monday, May 4th. Barclays boosted their price objective on Becton, Dickinson and Company from $202.00 to $204.00 and gave the company an “overweight” rating in a report on Monday, May 11th. The Goldman Sachs Group reduced their price target on Becton, Dickinson and Company from $156.00 to $150.00 and set a “neutral” rating for the company in a research report on Wednesday, May 27th. Finally, Bank of America lowered their price objective on Becton, Dickinson and Company from $177.00 to $170.00 in a research report on Friday, June 12th. Eight analysts have rated the stock with a Buy rating, eight have issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Hold” and an average target price of $180.93.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.